Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception.
Considerable preclinical research has demonstrated the efficacy of Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the primary psychoactive constituent of Cannabis sativa, in a wide variety of animal models of pain, but few studies have examined other phytocannabinoids. Indeed, other plant-derived cannabinoids, including cannabidiol (CBD), cannabinol (CBN), and cannabichromene (CBC) elicit antinociceptive effects in some assays. In contrast, tetrahydrocannabivarin (THCV), another component of cannabis, antagonizes the pharmacological effects of Delta(9)-THC. These results suggest that various constituents of this plant may interact in a complex manner to modulate pain. The primary purpose of the present study was to assess the antinociceptive effects of these other prevalent phytocannabinoids in the acetic acid stretching test, a rodent visceral pain model. Of the cannabinoid compounds tested, Delta(9)-THC and CBN bound to the CB(1) receptor and produced antinociceptive effects. The CB(1) receptor antagonist, rimonabant, but not the CB(2) receptor antagonist, SR144528, blocked the antinociceptive effects of both compounds. Although THCV bound to the CB(1) receptor with similar affinity as Delta(9)-THC, it had no effects when administered alone, but antagonized the antinociceptive effects of Delta(9)-THC when both drugs were given in combination. Importantly, the antinociceptive effects of Delta(9)-THC and CBN occurred at lower doses than those necessary to produce locomotor suppression, suggesting motor dysfunction did not account for the decreases in acetic acid-induced abdominal stretching. These data raise the intriguing possibility that other constituents of cannabis can be used to modify the pharmacological effects of Delta(9)-THC by either eliciting antinociceptive effects (i.e., CBN) or antagonizing (i.e., THCV) the actions of Delta(9)-THC.
Booker
Lamont
L
Department of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298, USA.
Naidu
Pattipati S
PS
Razdan
Raj K
RK
Mahadevan
Anu
A
Lichtman
Aron H
AH
D019342:Acetic Acid; D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology; D001892:Camphanes / Q000494:pharmacology; D002186:Cannabinoids / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D003511:Cyclohexanols / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D013759:Dronabinol / Q000494:pharmacology; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009043:Motor Activity / Q000187:drug effects; D010146:Pain / Q000139:chemically induced / Q000517:prevention & control*; D010147:Pain Measurement / Q000187:drug effects*; D010880:Piperidines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D012333:RNA, Messenger / Q000096:biosynthesis; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000378:metabolism; D043885:Receptor, Cannabinoid, CB2 / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000378:metabolism; D000077285:Rimonabant
D000700:Analgesics; D019440:Anti-Obesity Agents; D001892:Camphanes; D002186:Cannabinoids; D003511:Cyclohexanols; D010880:Piperidines; D011720:Pyrazoles; D012333:RNA, Messenger; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; C110630:SR 144528; D013759:Dronabinol; C054649:3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol; D019342:Acetic Acid; D000077285:Rimonabant
Proc Natl Acad Sci U S A. 1999 May 11;96(10):5780-5
10318961
Endocrinology. 2005 Oct;146(10):4292-301
15994343
Arch Int Pharmacodyn Ther. 1977 Jul;228(1):68-72
921403
J Med Chem. 1991 Nov;34(11):3310-6
1659638
Eur J Pharmacol. 2006 Sep 28;546(1-3):60-8
16919265
Science. 2005 Oct 14;310(5746):329-32
16224028
Psychopharmacology (Berl). 2006 Jun;186(2):226-34
16572263
Br J Pharmacol. 2007 Mar;150(5):586-94
17245367
Synapse. 2004 Sep 15;53(4):208-13
15266552
J Pharmacol Exp Ther. 2005 Jul;314(1):329-37
15831444
Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):12198-203
10518599
FASEB J. 1988 Nov;2(14):3022-6
2846397
Nature. 2005 Jun 23;435(7045):1108-12
15973410
J Control Release. 2003 Dec 12;93(3):377-87
14644587
J Pharmacol Exp Ther. 1992 Dec;263(3):1118-26
1335057
Brain Res. 2008 Jan 10;1188:157-64
18021759
Biochem J. 1991 Oct 1;279 ( Pt 1):129-34
1718258
J Forensic Sci. 1988 Nov;33(6):1385-404
3204345
Psychopharmacologia. 1975;40(4):285-95
1170585
J Pharmacol Exp Ther. 2003 Sep;306(3):880-8
12808005
Mol Pharmacol. 1988 Nov;34(5):605-13
2848184
Int Immunopharmacol. 2002 Jan;2(1):69-82
11789671
Gastroenterology. 2005 Aug;129(2):437-53
16083701
Eur J Biochem. 1995 Aug 15;232(1):54-61
7556170
J Pharmacol Exp Ther. 1993 Apr;265(1):218-26
8474008
Nature. 1993 Sep 2;365(6441):61-5
7689702
Psychopharmacology (Berl). 1979 Mar 28;61(3):281-5
156380
Br J Pharmacol. 2007 Mar;150(5):613-23
17245363
Br J Pharmacol. 2005 Dec;146(7):917-26
16205722
Psychopharmacologia. 1976;46(1):83-5
1257370
J Forensic Sci. 2000 Jan;45(1):24-30
10641915
J Pharmacol Exp Ther. 1995 Jun;273(3):1235-44
7791096
Pharmacol Rev. 2002 Jun;54(2):161-202
12037135
Naunyn Schmiedebergs Arch Pharmacol. 2004 Mar;369(3):294-9
14963641
Eur J Biochem. 1993 May 15;214(1):173-80
8508790
Pharmacol Biochem Behav. 1984 Jul;21(1):61-5
6087379
Pharmacol Biochem Behav. 1991 Nov;40(3):471-8
1666911
Life Sci. 2005 Dec 22;78(5):539-48
16199061
Mol Pharmacol. 2005 Nov;68(5):1196-202
16051747
Inflammation. 1988 Aug;12(4):361-71
3169967
J Pharmacol Exp Ther. 1996 Sep;278(3):989-99
8819477
Nature. 1990 Aug 9;346(6284):561-4
2165569
Arch Int Pharmacodyn Ther. 1972 Mar;196(1):133-45
5059359
Int J Obes (Lond). 2006 Apr;30 Suppl 1:S7-S12
16570107